Search Results

There are 762 results for: content related to: Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis

  1. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2209–2217, Casper Steenholdt, Magid Al-khalaf, Jørn Brynskov, Klaus Bendtzen, Ole Ø. Thomsen and Mark A. Ainsworth

    Article first published online : 16 FEB 2012, DOI: 10.1002/ibd.22910

  2. You have free access to this content
    Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 37, Issue 12, June 2013, Pages: 1172–1183, C. Steenholdt, Y. Palarasah, K. Bendtzen, A. Teisner, J. Brynskov, B. Teisner and C. H. Nielsen

    Article first published online : 7 MAY 2013, DOI: 10.1111/apt.12330

  3. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

    Inflammatory Bowel Diseases

    Volume 16, Issue 11, November 2010, Pages: 1898–1904, Akihiro Yamada, Koji Sono, Nobuo Hosoe, Nobuo Takada and Yasuo Suzuki

    Article first published online : 22 MAR 2010, DOI: 10.1002/ibd.21259

  4. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

    Inflammatory Bowel Diseases

    Volume 18, Issue 9, September 2012, Pages: 1628–1633, Uri Kopylov, Yoav Mazor, Miri Yavzori, Ella Fudim, Lior Katz, Daniel Coscas, Orit Picard, Yehuda Chowers, Rami Eliakim and Shomron Ben-Horin

    Article first published online : 29 OCT 2011, DOI: 10.1002/ibd.21919

  5. You have free access to this content
    Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 34, Issue 1, July 2011, Pages: 51–58, C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov and M. A. Ainsworth

    Article first published online : 3 MAY 2011, DOI: 10.1111/j.1365-2036.2011.04682.x

  6. You have free access to this content
    The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 2, January 2011, Pages: 243–250, C. I. De Bie, T. Z. Hummel, A. Kindermann, F. T. M. Kokke, G. M. Damen, C. M. F. Kneepkens, P. F. Van Rheenen, J. J. Schweizer, J. H. Hoekstra, O. F. Norbruis, W. E. Tjon a Ten, A. C. Vreugdenhil, J. M. Deckers-Kocken, C. F. M. Gijsbers, J. C. Escher and L. De Ridder

    Article first published online : 14 NOV 2010, DOI: 10.1111/j.1365-2036.2010.04507.x

  7. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review

    Inflammatory Bowel Diseases

    Volume 15, Issue 8, August 2009, Pages: 1264–1275, Andrea Cassinotti and Simon Travis

    Article first published online : 23 FEB 2009, DOI: 10.1002/ibd.20899

  8. You have free access to this content
    Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 5, May 2012, Pages: 985–1002, Charlotte I. de Bie, Johanna C. Escher and Lissy de Ridder

    Article first published online : 20 SEP 2011, DOI: 10.1002/ibd.21871

  9. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study

    Inflammatory Bowel Diseases

    Volume 17, Issue 10, October 2011, Pages: 2144–2152, Valérie Crombé, Julia Salleron, Guillaume Savoye, Jean-Louis Dupas, Gwénola Vernier-Massouille, Eric Lerebours, Antoine Cortot, Véronique Merle, Francis Vasseur, Dominique Turck, Corinne Gower-Rousseau, Marc Lémann, Jean-Frédéric Colombel and Alain Duhamel

    Article first published online : 1 FEB 2011, DOI: 10.1002/ibd.21615

  10. You have free access to this content
    Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels

    Clinical & Experimental Immunology

    Volume 172, Issue 1, April 2013, Pages: 54–62, L. Semerano, J. Biton, L. Delavallée, E. Duvallet, E. Assier, N. Bessis, E. Bernier, O. Dhellin, G. Grouard-Vogel and M.-C. Boissier

    Article first published online : 10 MAR 2013, DOI: 10.1111/cei.12040

  11. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

    Inflammatory Bowel Diseases

    Volume 15, Issue 9, September 2009, Pages: 1295–1301, Fabian Schnitzler, Herma Fidder, Marc Ferrante, Maja Noman, Ingrid Arijs, Gert Van Assche, Ilse Hoffman, Kristel Van Steen, Séverine Vermeire and Paul Rutgeerts

    Article first published online : 1 APR 2009, DOI: 10.1002/ibd.20927

  12. You have free access to this content
    Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 7, October 2012, Pages: 650–659, C. Steenholdt, C. Enevold, M. A. Ainsworth, J. Brynskov, O. Ø. Thomsen and K. Bendtzen

    Article first published online : 5 AUG 2012, DOI: 10.1111/apt.12010

  13. You have free access to this content
    eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 9, November 2012, Pages: 840–849, N. Pedersen, M. Elkjaer, D. Duricova, J. Burisch, C. Dobrzanski, N. N. Andersen, T. Jess, F. Bendtsen, E. Langholz, S. Leotta, T. Knudsen, N. Thorsgaard and P. Munkholm

    Article first published online : 12 SEP 2012, DOI: 10.1111/apt.12043

  14. Gastroenterologists' prescribing of infliximab for Crohn's disease: A national survey

    Inflammatory Bowel Diseases

    Volume 15, Issue 10, October 2009, Pages: 1467–1475, Meaghan St. Charles, Sheila R. Weiss Smith, Robert Beardsley, Donald O. Fedder, Olivia Carter-Pokras and Raymond K. Cross

    Article first published online : 5 MAR 2009, DOI: 10.1002/ibd.20904

  15. You have free access to this content
    Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 8, October 2012, Pages: 765–771, N. Vande Casteele, D. J. Buurman, M. G. G. Sturkenboom, J. H. Kleibeuker, S. Vermeire, T. Rispens, D. van der Kleij, A. Gils and G. Dijkstra

    Article first published online : 28 AUG 2012, DOI: 10.1111/apt.12030

  16. Predictors of response to infliximab in paediatric perianal Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 8, October 2014, Pages: 917–929, C. Dupont-Lucas, A. Dabadie, C. Alberti and F. M. Ruemmele, for the GETAID (Groupe d'Etude thérapeutique des Affections Inflammatoires du Tube Digestif) pédiatrique

    Article first published online : 21 AUG 2014, DOI: 10.1111/apt.12928

  17. You have free access to this content
    Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 5, March 2010, Pages: 553–560, Y. ZABANA, E. DOMÈNECH, M. MAÑOSA, E. GARCIA-PLANELLA, I. BERNAL, E. CABRÉ and M. A. GASSULL

    Article first published online : 30 NOV 2009, DOI: 10.1111/j.1365-2036.2009.04206.x

  18. Endoscopic monitoring of infliximab therapy in Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 4, April 2011, Pages: 947–953, Clas-Göran af Björkesten, Urpo Nieminen, Ulla Turunen, Perttu E. Arkkila, Taina Sipponen and Martti A. Färkkilä

    Article first published online : 21 SEP 2010, DOI: 10.1002/ibd.21439

  19. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 6, June 2014, Pages: 1177–1185, Michael J Hayes, Adam C Stein and Atsushi Sakuraba

    Article first published online : 15 MAY 2014, DOI: 10.1111/jgh.12517

  20. Predictors of early response to infliximab in patients with ulcerative colitis

    Inflammatory Bowel Diseases

    Volume 13, Issue 2, February 2007, Pages: 123–128, Marc Ferrante, Séverine Vermeire, Konstantinos H. Katsanos, Maja Noman, Gert Van Assche, Fabian Schnitzler, Ingrid Arijs, Gert De Hertogh, Ilse Hoffman, Karel Geboes and Paul Rutgeerts

    Article first published online : 19 DEC 2006, DOI: 10.1002/ibd.20054